Jeffrey Kuethe

Dr. Jeffrey Kuethe


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Circulation
Verified
Journal Article
Open access
DJDouglas G. Johns
Douglas G. Johns
LCLouis-Charles Campeau
Louis-Charles Campeau
PBPuja Banka
Puja Banka
ABAn Bautmans
An Bautmans
TBTjerk Bueters
Tjerk Bueters
HWHarold B. Wood
Harold B. Wood
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design. Methods: Novel mRNA display screening technology was used to identify lead chemical matter, which was then optimized by applying structure-based drug design enabled by novel synthetic chemistry to identify macrocyclic peptide (MK-0616) with exquisite potency and selectivity for PCSK9. Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics. In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol). Results: MK-0616 displayed high affinity ( K i = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic. In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84–103) of free, unbound plasma PCSK9; in participants on statin therapy, multiple–oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43–85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616. Conclusions: This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.

25 February 2005 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
JKJeffrey Kuethe
Jeffrey Kuethe
AWAudrey Wong
Audrey Wong
CQChuanxing Qu
Chuanxing Qu
JSJacqueline Smitrovich
Jacqueline Smitrovich
IDIan W. Davies
Ian W. Davies
DHDavid L. Hughes
David L. Hughes


3 September 2003 in Organic Letters
Verified
Journal Article
Closed access
JKJeffrey Kuethe
Jeffrey Kuethe
AWAudrey Wong
Audrey Wong
IDIan W. Davies
Ian W. Davies

24 March 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HLHongming Li
Hongming Li
DTDavid A. Thaisrivongs
David A. Thaisrivongs
GSGao Shang
Gao Shang
YCYonggang Chen
Yonggang Chen
QCQinghao Chen
Qinghao Chen
JYJingjun Yin
Jingjun Yin

24 March 2005 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
JKJeffrey Kuethe
Jeffrey Kuethe
AWAudrey Wong
Audrey Wong
MJMichel Journet
Michel Journet
IDIan W. Davies
Ian W. Davies